Capital Advisors Ltd’s Dare Bioscience DARE Stock Holding History

Capital Advisors Ltd’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17	Closed	–	–	1434
2024 Q1	$0	Buy	+17	New	+$83	﹤0.01%	1392

Other funds holding DARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Capital Advisors Ltd's DARE Position: Q2 2024 in Review

Capital Advisors Ltd sold out of Dare Bioscience (DARE) in Q2 2024, closing a stake of 17 shares.

Capital Advisors Ltd first reported a position in DARE in Q1 2024 and held it in 1 quarter. The position peaked at $0 in Q1 2024. 27 funds tracked by Wall St. Rank hold DARE as of Q2 2024.

Capital Advisors Ltd reported no remaining Dare Bioscience position as of Q2 2024 after selling out during the quarter.
Capital Advisors Ltd sold 17 Dare Bioscience shares in Q2 2024.
Capital Advisors Ltd first reported a position in Dare Bioscience in Q1 2024 and held it in 1 quarter.
Capital Advisors Ltd's Dare Bioscience position peaked at $0 in Q1 2024.
27 funds tracked by Wall St. Rank held Dare Bioscience as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.